Question · asked by 1 review
Summary of findings: levofloxacin for inhalation solution vs tobramycin: Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations
- Population
- adults and children aged over 12 with CF and P aeruginosa
- Intervention
- Summary of findings: levofloxacin for inhalation solution
- Comparison
- tobramycin
- Outcome
- Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations
Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: levofloxacin for inhalation solution vs tobramycin Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · adults and children aged over 12 with CF and P aeruginosa Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty). Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane Headline outcomes only | RR 0.62 [0.4, 0.98] | 1 study · 282 participants | High |
Summary of findings: levofloxacin for inhalation solution vs tobramycin Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · adults and children aged over 12 with CF and P aeruginosa Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty). Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2018) · Cochrane Headline outcomes onlyearlier version CD001021.PUB3, superseded | RR 0.62 [0.4, 0.98] | 1 study · 282 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.